Haemonetics
About: Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
Employees: 3,657
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
40% more repeat investments, than reductions
Existing positions increased: 123 | Existing positions reduced: 88
33% more funds holding in top 10
Funds holding in top 10: 3 [Q3] → 4 (+1) [Q4]
17% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 41
4.43% more ownership
Funds ownership: 108.19% [Q3] → 112.61% (+4.43%) [Q4]
2% more call options, than puts
Call options by funds: $42.5M | Put options by funds: $41.7M
1% more funds holding
Funds holding: 303 [Q3] → 305 (+2) [Q4]
1% less capital invested
Capital invested by funds: $4.45B [Q3] → $4.42B (-$31.7M) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Raymond James Andrew Cooper 18% 1-year accuracy 4 / 22 met price target | 52%upside $105 | Strong Buy Reiterated | 9 May 2025 |
Needham Mike Matson 38% 1-year accuracy 42 / 112 met price target | 21%upside $84 | Buy Maintained | 8 May 2025 |
Financial journalist opinion
Based on 8 articles about HAE published over the past 30 days
